Last week, Incyte Corporation (INCY) received a milestone payment of $60 million from Novartis (NVS) pertaining to the reimbursement of Jakavi in Europe. The drug has been approved by the European Commission to treat adults suffering from primary myelofibrosis (MF), post-polycythemia vera MF or post-essential thrombocythemia MF. It is a common practice of small pharma companies to enter into agreements with larger pharma companies for … Continue reading Biotech Stock Incyte Receives $60M Milestone Payment

Good news flowed in at Regeneron Pharmaceuticals (REGN) when the FDA cleared the company’s highly successful injectable eye drug for macular edema following retinal vein occlusion (RVO), a common retinal vascular disorder. Approval for the broad RVO indication includes sub-indications like, macular edema following branch retinal vein occlusion (BRVO) and macular edema following central retinal vein occlusion (CRVO). We remind investors that Eylea is already … Continue reading Biotech Stock News: Regeneron’s Eylea Gets An Important Approval From FDA

Shares of Sunesis Pharmaceuticals, Inc (SNSS) plunged significantly after the company announced that its phase III trial, VALOR, failed to meet its primary endpoint. The randomized, double-blind, placebo-controlled trial (n=711) evaluated the efficacy of Qinprezo (vosaroxin) and cytarabine in patients suffering from first relapsed or refractory acute myeloid leukemia (AML). The trial failed to reach its primary endpoint of a statistically significant improvement in overall … Continue reading Sunesis Pharmaceuticals Stock Down : Biotech Trial Failure

The oft-trodden path for a startup biotech is to aim for either a buyout or an IPO—or at minimum, a partnership with a big pharmaceutical company—before dealing with the hefty price tag of a Phase 3 study. One local biotech, however, took on the risk of bucking that trend—and succeeded. That story and much more below. Boston and Hayward, CA-based Intarcia turned heads earlier this … Continue reading Biotech Stocks: A Look At the Most Promising Biotech Stocks

Here we have a close look at some of the major Biotech Stocks which have shown tremendous promise over the past few weeks. Investors are all recommended to closely monitor these stocks over the coming months as some movement is expected from these stocks. Portola Pharmaceuticals (PTLA), a biopharmaceutical company, develops product candidates in the fields of thrombosis and hematology. This stock closed up 4.1% … Continue reading Biotech Stocks in News: Major Biotech Stocks to Focus On

Mergers and acquisitions were back in the news last week with Auxilium Pharmaceuticals (AUXL) being the target this time around. The company, which is looking to acquire QLT Inc (QLTI), received a proposal from Endo International plc (ENDP). Other updates last week include the usual regulatory and pipeline-related news. Gilead remained in the news thanks yet again to its hepatitis C virus (HCV) treatment, Sovaldi. … Continue reading Biotech Stock News: A Weekly Analysis of Major Biotech Stocks